Dual inhibition of IGF-1R and ErbB3 enhances the activity of gemcitabine and nab-paclitaxel in preclinical models of pancreatic cancer

AJ Camblin, EA Pace, S Adams, MD Curley… - Clinical Cancer …, 2018 - AACR
Purpose: Insulin-like growth factor receptor 1 (IGF-1R) is critically involved in pancreatic
cancer pathophysiology, promoting cancer cell survival and therapeutic resistance …
被引用次数：54 相关文章

Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer

AJ Camblin, EA Pace, S Adams… - … : an official journal …, 2018 - pubmed.ncbi.nlm.nih.gov
Purpose: Insulin-like growth factor receptor 1 (IGF-1R) is critically involved in pancreatic
cancer pathophysiology, promoting cancer cell survival and therapeutic resistance …
[PDF] researchgate.net

[PDF][PDF] Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer

AJ Camblin, EA Pace, S Adams, MD Curley… - researchgate.net
Purpose: Insulin-like growth factor receptor 1 (IGF-1R) is critically involved in pancreatic
cancer pathophysiology, promoting cancer cell survival and therapeutic resistance …

Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.

AJ Camblin, EA Pace, S Adams, MD Curley… - … Cancer Research: an …, 2018 - europepmc.org
Purpose: Insulin-like growth factor receptor 1 (IGF-1R) is critically involved in pancreatic
cancer pathophysiology, promoting cancer cell survival and therapeutic resistance …